Rory Shallis, MD

2025

• Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab

  Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?

  Badar T, E.l. Kettani M, Shah K, Jamy O, Shallis R, Diebold K, Coltoff A, Goldberg A, Patel A, Bewersdorf J, Foucar C, Abaza Y, Palmisiano N, DuVall A, Kota V, Zeidan A, Atallah E, Litzow M. Should we treat TP53-mutated high-risk myeloid neoplasms in older patients? Journal Of Clinical Oncology 2025, 43: 6538-6538. DOI: 10.1200/jco.2025.43.16_suppl.6538.

  Peer-Reviewed Original Research

  Concepts

• Heterogeneity in outcomes of TP53‐mutated myeloproliferative neoplasms based on disease phenotype and mutational status

  Badar T, Foran J, Bewersdorf J, Wang Y, Coltoff A, Kettani M, Shah K, Oliva F, Lin C, Jamy O, Diebold K, Shallis R, Siddon A, Katkov D, Schoen A, Khan I, Foucar C, Atallah E, Goldberg A, Patel A. Heterogeneity in outcomes of TP53‐mutated myeloproliferative neoplasms based on disease phenotype and mutational status. British Journal Of Haematology 2025 PMID: 40400334, DOI: 10.1111/bjh.20187.

  Peer-Reviewed Original Research

  Altmetric

• Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy

  Shaw R, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Patel A. Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Advances 2025, 9: 2453-2457. PMID: 39969200, PMCID: PMC12144506, DOI: 10.1182/bloodadvances.2024015712.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms

  Goldberg L, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Cursio J, Patel A. Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms. Blood Neoplasia 2025, 2: 100089. DOI: 10.1016/j.bneo.2025.100089.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  Shallis R, Weiss J, Winer E, Badar T, Swaroop A, Doukas P, Geramita E, Le H, Agarwal S, Merl M, Abaza Y, Im A, Litzow M, Podoltsev N. Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia & Lymphoma 2025, ahead-of-print: 1-5. PMID: 40294060, DOI: 10.1080/10428194.2025.2496339.

  Peer-Reviewed Original Research

  Citations

  Altmetric

• CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTER STUDY

  Filimon S, Ghamari A, Vakilpour A, Patel R, Achar R, Akhter N, Shallis R, DeCara J, Anazco F, Altman J, Smith A, Matthews A, Lai C, Brunner A, Farina K, Gilman H, Neilan T, Upadhyay D, Patel A, Tremblay D, Scherrer-Crosbie M. CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTER STUDY. Journal Of The American College Of Cardiology 2025, 85: 2865. DOI: 10.1016/s0735-1097(25)03349-2.

  Peer-Reviewed Original Research

  Concepts

• Real‐World Outcomes of Relapsed/Refractory Core‐Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study

  Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Nai N, Foucar C, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Murthy S, Badar T, Patel A. Real‐World Outcomes of Relapsed/Refractory Core‐Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study. American Journal Of Hematology 2025, 100: 1082-1085. PMID: 40062542, PMCID: PMC12068978, DOI: 10.1002/ajh.27664.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

  Greenberg P, Stone R, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett J, Borate U, Brunner A, Chai-Ho W, Curtin P, DeZern A, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths E, Haque T, Jacoby M, Jonas B, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness L, McCurdy S, McMahon C, Odenike O, Osman A, Reddy V, Sallman D, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal Of The National Comprehensive Cancer Network 2025, 23: 66-75. PMID: 40073835, DOI: 10.6004/jnccn.2025.0013.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  MeSH Keywords and Concepts

• Real-World Analysis of Strategies to Prevent Thrombosis and Bleeding in Adults with ALL Treated with Asparaginase

  Mort J, Brighton D, Mautner B, Pierce E, Ghamsari F, Allen C, D’souza D, Patel I, Lawson J, Jackson C, Abernathy K, Yelvington B, Miller R, Dholaria B, Wolfe H, Infield J, Locke S, Shallis R, Duong V, Reed D, Walsh K, LeBlanc T, Keng M, Horton B, Chaer F. Real-World Analysis of Strategies to Prevent Thrombosis and Bleeding in Adults with ALL Treated with Asparaginase. Blood Vessels Thrombosis & Hemostasis 2025, 100065. DOI: 10.1016/j.bvth.2025.100065.

  Peer-Reviewed Original Research

  Concepts